Johnson & Johnson (JNJ HM) stock market data APIs
€179.1506
-0.72(-0.4%)
as of December 17, 2025
Try our APIs with
free plan!
Johnson & Johnson Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for JNJ.HM.
Prev. Close
179.1506
Open
178.4306
High
180.7274
Low
177.1958
52 wk Range
126.3854-182.72
Market Cap
385 769 M
Dividends (Yield)
0.0224
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Johnson & Johnson data using free add-ons & libraries
Get Johnson & Johnson Fundamental Data
Johnson & Johnson Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Johnson & Johnson News
New
U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)
RYBREVANT FASPRO™, the first and only subcutaneous therapy for patients with EGFR-mutated NSCLC, reduces administration time from hours to minutes and significantly reduces administration-related re...
BofA Sees J&J’s Premium Multiple as Justified
Johnson & Johnson (NYSE:JNJ) is included among the 12 Best Dogs of the Dow to Invest in.BofA Sees J&J’s Premium Multiple as Justified On December 15, BofA raised its price target on Johnson & Johns...
RIS Rx Appoints Stuart McGuigan to Board of Directors
IRVINE, Calif., December 17, 2025--(BUSINESS WIRE)--RIS Rx, a healthcare technology company offering gross-to-net (GTN) revenue protection and saving more than $1 billion for the world’s leading pha...
Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?
Johnson & Johnson (JNJ) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
